Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | KCNMA1 | Q12791 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 11/20 | 0.43 |
| ▸ | MGAM | O43451 | 10/20 | 0.43 |
| ▸ | AMY1A | P0DUB6 | 10/20 | 0.43 |
| ▸ | SI | P14410 | 10/20 | 0.43 |
| ▸ | MGAM2 | Q2M2H8 | 10/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | SLC9A1 | P19634 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.43 |
| ▸ | F12 | P00748 | 3/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21904738 | 1.00 | DGAT1 (0.51) | DGAT1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL3893181 | 0.94 | DGAT1 (0.57) | DGAT1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL21073734 | 0.91 | DGAT1 (0.51) | DGAT1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL21904737 | 0.89 | DGAT1 (0.49) | DGAT1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL29031460 | 0.89 | DGAT1 (0.49) | DGAT1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL2732055 | 0.89 | DGAT1 (0.49) | DGAT1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL29803806 | 0.80 | TUBB4A (0.41) | KMT2A | |
| SCHEMBL29874491 | 0.80 | TUBB4A (0.41) | DGAT1KMT2AMAPTHTTNPSR1 | |
| SCHEMBL29475370 | 0.79 | PKM (0.41) | KMT2AMAPTHTTKDM4EKCNMA1 | |
| SCHEMBL30495312 | 0.77 | DGAT1 (0.47) | DGAT1KMT2AMAPTHTTNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250134812-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS : SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | KORANEX CAPITAL (CA) | 2025-05-01 | — | — | US | claimed |
| WO-2023141693-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | KORANEX CAPITAL (CA) | 2023-08-03 | — | — | WO | claimed |
| WO-2023141692-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | KORANEX CAPITAL (CA) | 2023-08-03 | — | — | WO | claimed |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | INSTITUT CURIE (FR) | 2026-05-21 | — | — | US | disclosed |
| US-20260124177-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | NOVITA PHARMACEUTICALS, INC. (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4096662-B1 | PROCESS FOR PREPARATION OF LASMIDITAN | ALIVUS LIFE SCIENCES LTD (IN) | 2026-03-25 | — | — | EP | disclosed |
| US-12577236-B2 | Processes for preparation of Tezacaftor | LAURUS LABS LIMITED (IN) | 2026-03-17 | — | — | US | disclosed |
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | INSTITUT CURIE (FR) | 2026-01-20 | — | — | US | disclosed |
| US-12508245-B2 | Co-therapies including a metastasis inhibitor | NOVITA PHARMACEUTICALS, INC. (US) | 2025-12-30 | — | — | US | disclosed |
| US-20250368657-A1 | METHODS FOR INHIBITING FASCIN | NOVITA PHARMACEUTICALS INC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250333411-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | CORNELL UNIVERSITY (US) | 2025-10-30 | — | — | US | disclosed |
| WO-2010022177-A2 | PRODRUGS OF METHYL HYDROGEN FUMARATE, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | XENOPORT, INC. (US) | 2010-02-25 | — | — | WO | disclosed |
| US-20080221108-A1 | Anthranilic Acid Derivatives As Hm74A Receptor Agonists | SMITHKLINE BEECHAM CORPORATION | 2008-09-11 | — | — | US | disclosed |
| EP-1951746-A1 | SOLUTION-PHASE SYNTHESIS OF LEUPROLIDE AND ITS INTERMEDIATES | NANOKEM S.A. (UY) | 2008-08-06 | — | — | EP | disclosed |
| EP-1848699-A1 | ANTHRANILIC ACID DERIVATIVES AS HM74A RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-10-31 | — | — | EP | disclosed |
| WO-2007059922-A1 | SYNTHESIS OF CARBON ACID AMIDES | SYNTHACON GMBH (DE) | 2007-05-31 | — | — | WO | disclosed |
| WO-2007059921-A1 | SOLUTION-PHASE SYNTHESIS OF LEUPROLIDE AND ITS INTERMEDIATES | NANOKEM S.A. (UY) | 2007-05-31 | — | — | WO | disclosed |
| WO-2006085112-A1 | ANTHRANILIC ACID DERIVATIVES AS HM74A RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-08-17 | — | — | WO | disclosed |
| EP-1670749-A1 | 2-SUBSTITUTED BENZOIC ACID DERIVATIVES AS HM74A RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2006-06-21 | — | — | EP | disclosed |
| WO-2005016870-A1 | 2-SUBSTITUTED BENZOIC ACID DERIVATIVES AS HM74A RECEPTOR AGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12527854-B2 | Methods of producing Shiga toxin B-subunit (STxB) monomers and oligomers, and uses thereof | STXBP1, RNGTT, UPF1 | DGAT1 3742/4885KMT2A 1584/4885MAPT 2925/4885 |
| US-12577236-B2 | Processes for preparation of Tezacaftor | CYP4A11, F9, CYP3A4 | DGAT1 2456/4885KMT2A 398/4885MAPT 3497/4885 |
| US-12508245-B2 | Co-therapies including a metastasis inhibitor | PDCD1, CD274, PDCD4 | DGAT1 4238/4885KMT2A 2544/4885MAPT 148/4885 |
| US-20250333411-A1 | COMPOUNDS AND METHODS FOR INHIBITING FASCIN | FSCN1, MTPN, MYOF | DGAT1 673/4885KMT2A 4757/4885MAPT 352/4885 |
| US-20250134812-A1 | SYNTHETIC GLYCOLIPIDS AND GLYCOLIPOSOME COMPOSITIONS : SUITABLE FOR CARGO DELIVERY TO THE CENTRAL NERVOUS SYSTEM | SGMS2, SGMS1, GBA2 | DGAT1 784/4885KMT2A 1936/4885MAPT 671/4885 |
| US-20260137765-A1 | METHODS OF PRODUCING SHIGA TOXIN B-SUBUNIT (STXB) MONOMERS AND OLIGOMERS, AND USES THEREOF | STXBP1, HBB, UPF1 | DGAT1 3071/4885KMT2A 1769/4885MAPT 3405/4885 |
| US-20250368657-A1 | METHODS FOR INHIBITING FASCIN | FSCN1, NLN, TNNI3 | DGAT1 1790/4885KMT2A 4603/4885MAPT 1238/4885 |
| US-20080221108-A1 | Anthranilic Acid Derivatives As Hm74A Receptor Agonists | ANTXR2, GPR84, HCAR1 | DGAT1 4187/4885KMT2A 1142/4885MAPT 4865/4885 |
| US-20260124177-A1 | CO-THERAPIES INCLUDING A METASTASIS INHIBITOR | CCR10, CCR4, OGFR | DGAT1 3542/4885KMT2A 3991/4885MAPT 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.